TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›CNTX›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Context Therapeutics Inc. (CNTX) financials

Income statement

Context Therapeutics Inc. (CNTX) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$2.57M-$10.5M-$15.4M-$25.1M-$29.9M-$39.7M
Net income$6.64M-$10.5M-$14.8M-$24.0M-$26.7M-$36.1M
EPS (diluted)-$3.96-$3.69-$0.93-$1.50-$0.46-$0.38

Cash flow

Context Therapeutics Inc. (CNTX) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$1.03M-$8.80M-$13.5M-$21.0M-$14.6M-$26.4M
Capital expenditures—$0.00$36.8K$0.00$7.32K$33.9K
Free cash flow—-$8.80M-$13.6M-$21.0M-$14.6M-$26.4M

Balance sheet

Context Therapeutics Inc. (CNTX) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$291K$49.6M$35.5M$14.4M$94.4M$66.0M
Total assets$467K$51.3M$38.0M$16.1M$98.1M$68.5M
Total liabilities$9.62M$3.03M$3.21M$4.19M$2.86M$8.02M
Shareholders' equity-$16.9M$48.3M$34.8M$11.9M$95.3M$60.5M
Retained earnings-$18.8M-$29.3M-$44.1M-$68.1M-$94.8M-$131M
Shares (wtd avg diluted)2.05M2.83M16.0M16.0M58.4M95.2M

Every figure is extracted from Context Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Context Therapeutics Inc.'s free cash flow?
-$26.4M in FY2025 (operating cash flow -$26.4M minus $33.9K of capital expenditures), from the SEC cash-flow statement.
Does CNTX pay a dividend?
Context Therapeutics Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full CNTX analysis — verdict, score & filings →Is CNTX a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.